The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

NCT04179890 · clinicaltrials.gov ↗

COMPLETED

Status

462

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous, Non-Small Cell Lung Cancer

Interventions

DRUG: Afatinib (Gi(l)otrif®)
DRUG: Erlotinib (Tarceva®)
DRUG: Gefitinib (IRESSA®)
DRUG: Osimertinib (Tagrisso®)
DRUG: Afatinib (Gi(l)otrif®)
DRUG: Osimertinib (Tagrisso®)

Sponsor

Boehringer Ingelheim